Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIN457 open-label extension study in psoriatic arthritis
NL-OMON34933Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of secukinumab, sponsored by Novartis. Started Mar 2010; status: active, not recruiting.
02
Drugs
secukinumab
Beyond the preview
Go deeper on NL-OMON34933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34933.